Share Price and Basic Stock Data

Last Updated: November 9, 2024, 1:28 pm

Market Cap	7.80 Cr.
Current Price	18.0
High / Low	28.9/0.00
Stock P/E	9.07
Book Value	22.4
Dividend Yield	0.00 %
ROCE	2.68 %
ROE	8.23 %
Face Value	10.0
PEG Ratio	-2.92

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Dr Lalchandani Labs Ltd

Competitors of Dr Lalchandani Labs Ltd

Stock Name	Market Cap	Current Price	High / Low	Stock P/E	Book Value	Dividend Yield	ROCE	ROE	Face Value
Global Longlife Hospital and Research Ltd	38.4 Cr.	36.6	61.7/27.0		25.9	0.00 %	2.51 %	4.72 %	10.0
Gian Lifecare Ltd	21.6 Cr.	20.8	29.0/17.0	5.21	19.0	0.00 %	29.2 %	24.6 %	10.0
Fortis Malar Hospitals Ltd	101 Cr.	54.0	108/44.0		15.9	78.7 %	3.29 %	9.12 %	10.0
Family Care Hospitals Ltd	40.5 Cr.	7.50	10.4/6.23	0.98	2.67	0.00 %	15.4 %	24.1 %	10.0
Dr Lalchandani Labs Ltd	7.80 Cr.	18.0	28.9/0.00	9.07	22.4	0.00 %	2.68 %	8.23 %	10.0
Industry Average	27,088.85 Cr	815.13		51.19	89.64	3.80%	11.58%	12.32%	9.00

All Competitor Stocks of Dr Lalchandani Labs Ltd

Quarterly Result

Month	Mar 2019	Sep 2019	Mar 2020	Sep 2020	Mar 2021	Sep 2021	Mar 2022	Sep 2022	Mar 2023	Sep 2023	Mar 2024	Sep 2024
Sales	2.64	3.03	3.07	2.71	7.07	8.02	3.26	2.28	2.76	2.73	2.08	2.13
Expenses	1.95	2.30	2.53	2.14	5.40	6.07	2.81	2.46	2.50	2.38	1.04	1.59
Operating Profit	0.69	0.73	0.54	0.57	1.67	1.95	0.45	-0.18	0.26	0.35	1.04	0.54
OPM %	26.14%	24.09%	17.59%	21.03%	23.62%	24.31%	13.80%	-7.89%	9.42%	12.82%	50.00%	25.35%
Other Income	0.01	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.00	0.00	0.24	0.00
Interest	0.05	0.09	0.09	0.05	0.30	0.24	0.33	0.48	0.51	0.11	0.28	0.05
Depreciation	0.20	0.21	0.22	0.23	0.29	0.28	0.30	0.33	0.34	0.33	0.29	0.28
Profit before tax	0.45	0.43	0.23	0.29	1.08	1.43	-0.18	-0.98	-0.59	-0.09	0.71	0.21
Tax %	26.67%	0.00%	82.61%	24.14%	27.78%	25.17%	-22.22%	0.00%	0.00%	0.00%	0.00%	23.81%
Net Profit	0.34	0.43	0.04	0.23	0.79	1.07	-0.13	-0.97	-0.59	-0.09	0.71	0.15
EPS in Rs	0.78	0.99	0.09	0.53	1.82	2.47	-0.30	-2.24	-1.36	-0.21	1.64	0.35

Last Updated: November 6, 2024, 6:52 pm

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: October 23, 2024, 2:40 pm

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	2.79	5.26	6.10	9.78	11.28	5.04	4.81	4.21
Expenses	2.17	4.06	4.84	7.54	8.81	4.95	4.59	2.63
Operating Profit	0.62	1.20	1.26	2.24	2.47	0.09	0.22	1.58
OPM %	22.22%	22.81%	20.66%	22.90%	21.90%	1.79%	4.57%	37.53%
Other Income	0.03	0.01	0.00	0.00	0.00	0.00	1.40	0.24
Interest	0.16	0.14	0.18	0.35	0.60	0.99	0.38	0.33
Depreciation	0.13	0.35	0.42	0.52	0.59	0.66	0.62	0.57
Profit before tax	0.36	0.72	0.66	1.37	1.28	-1.56	0.62	0.92
Tax %	25.00%	26.39%	28.79%	26.28%	28.12%	0.00%	0.00%
Net Profit	0.26	0.53	0.47	1.01	0.93	-1.56	0.62	0.86
EPS in Rs	0.89	1.22	1.08	2.33	2.15	-3.60	1.43	1.99
Dividend Payout %	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	103.85%	-11.32%	114.89%	-7.92%	-267.74%	139.74%
Change in YoY Net Profit Growth (%)	0.00%	-115.17%	126.21%	-122.81%	-259.82%	407.49%

Dr Lalchandani Labs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2018-2019 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	-2%
3 Years:	-21%
TTM:	-23%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	226%

Stock Price CAGR
10 Years:	%
5 Years:	-3%
3 Years:	-12%
1 Year:	-49%

Return on Equity
10 Years:	%
5 Years:	0%
3 Years:	-5%
Last Year:	-8%

Last Updated: Unknown

Balance Sheet

Last Updated: October 15, 2024, 1:49 pm

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	2.93	4.33	4.33	4.33	4.33	4.33	4.33	4.33
Reserves	0.40	3.73	4.21	5.22	6.15	4.59	5.21	5.36
Borrowings	1.88	0.90	1.76	4.04	5.15	6.40	3.48	3.63
Other Liabilities	1.00	1.18	1.63	1.61	2.49	2.40	1.97	2.05
Total Liabilities	6.21	10.14	11.93	15.20	18.12	17.72	14.99	15.37
Fixed Assets	2.06	3.28	3.47	5.24	5.75	5.39	3.99	3.79
CWIP	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Investments	0.24	0.24	0.24	0.24	0.24	0.24	0.41	0.27
Other Assets	3.91	6.62	8.22	9.72	12.13	12.09	10.59	11.31
Total Assets	6.21	10.14	11.93	15.20	18.12	17.72	14.99	15.37

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	0.58	-0.45	-0.10	1.19	2.01	0.00	-0.22
Cash from Investing Activity +	-1.29	-1.95	-0.53	-2.26	-1.53	-0.20	1.00
Cash from Financing Activity +	1.57	3.51	0.85	1.71	0.16	-0.23	-1.59
Net Cash Flow	0.85	1.12	0.23	0.64	0.64	-0.43	-0.81

Free Cash Flow

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	-1.26	0.30	-0.50	-1.80	-2.68	-6.31	-3.26

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	149.14	126.99	199.25	148.54	136.55	359.93	356.65
Inventory Days	167.03	233.36	158.70	68.75	191.07	458.51	255.15
Days Payable	426.86	406.89	355.48	97.06	175.15	404.21	217.94
Cash Conversion Cycle	-110.69	-46.54	2.47	120.23	152.47	414.23	393.86
Working Capital Days	168.76	170.70	209.43	132.86	123.93	287.51	402.18
ROCE %		12.14%	8.72%	14.40%	12.87%	-3.68%	-2.68%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2018	Mar 2019	Sep 2019	Mar 2020	Sep 2020	Mar 2021	Sep 2021	Mar 2022	Sep 2022	Mar 2023	Sep 2023	Mar 2024
Promoters	60.78%	60.78%	60.78%	60.78%	60.78%	60.78%	60.78%	60.78%	60.78%	60.78%	60.78%	60.78%
Public	39.22%	39.22%	39.22%	39.22%	39.22%	39.22%	39.22%	39.22%	39.23%	39.22%	39.21%	39.22%
No. of Shareholders	168	151	144	143	143	143	151	157	162	164	159	165

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	1.43	-3.61	2.15	2.33	1.09
Diluted EPS (Rs.)	1.43	-3.61	2.15	2.33	1.09
Cash EPS (Rs.)	2.87	-2.08	3.51	3.52	2.07
Book Value[Excl.RevalReserv]/Share (Rs.)	22.02	20.56	24.16	22.01	19.68
Book Value[Incl.RevalReserv]/Share (Rs.)	22.02	20.59	24.20	22.04	19.71
Revenue From Operations / Share (Rs.)	11.10	11.63	26.03	22.57	14.09
PBDIT / Share (Rs.)	1.00	0.20	5.55	5.12	2.93
PBIT / Share (Rs.)	-0.43	-1.33	4.20	3.93	1.95
PBT / Share (Rs.)	1.43	-3.61	2.97	3.18	1.52
Net Profit / Share (Rs.)	1.43	-3.61	2.15	2.33	1.09
PBDIT Margin (%)	9.04	1.75	21.33	22.68	20.78
PBIT Margin (%)	-3.93	-11.40	16.12	17.41	13.85
PBT Margin (%)	12.83	-31.00	11.41	14.08	10.82
Net Profit Margin (%)	12.83	-31.00	8.27	10.34	7.76
Return on Networth / Equity (%)	6.47	-17.54	8.91	10.60	5.56
Return on Capital Employeed (%)	-1.89	-4.63	13.71	13.81	8.39
Return On Assets (%)	4.11	-8.82	5.14	6.65	3.97
Long Term Debt / Equity (X)	0.02	0.37	0.25	0.27	0.17
Total Debt / Equity (X)	0.36	0.52	0.38	0.35	0.17
Asset Turnover Ratio (%)	0.29	0.28	0.67	0.72	0.55
Current Ratio (X)	1.88	2.07	2.22	2.98	4.07
Quick Ratio (X)	1.60	1.78	1.90	2.75	3.80
Inventory Turnover Ratio (X)	1.39	0.00	0.00	0.00	0.00
Interest Coverage Ratio (X)	1.13	0.08	4.52	6.81	6.86
Interest Coverage Ratio (Post Tax) (X)	-0.49	-0.58	2.75	4.10	3.56
Enterprise Value (Cr.)	7.99	13.89	14.81	6.53	2.77
EV / Net Operating Revenue (X)	1.66	2.76	1.31	0.66	0.45
EV / EBITDA (X)	18.37	157.32	6.15	2.94	2.18
MarketCap / Net Operating Revenue (X)	1.42	2.44	1.27	0.61	0.57
Price / BV (X)	0.71	1.38	1.37	0.63	0.41
Price / Net Operating Revenue (X)	1.42	2.44	1.27	0.61	0.57
EarningsYield	0.09	-0.12	0.06	0.16	0.13

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Dr Lalchandani Labs Ltd as of November 15, 2024 is: 17.06

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 15, 2024, Dr Lalchandani Labs Ltd is Overvalued by 5.22% compared to the current share price 18.00

Intrinsic Value of Dr Lalchandani Labs Ltd as of November 15, 2024 is: 16.53

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 15, 2024, Dr Lalchandani Labs Ltd is Overvalued by 8.17% compared to the current share price 18.00

Last 5 Year EPS CAGR: -3.11%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock is trading at a low valuation with an average P/B ratio of 1.66 and average Dividend Yield of 3.63%. The company has higher reserves (4.36 cr) compared to borrowings (3.41 cr), indicating strong financial stability. The company has shown consistent growth in sales (6.16 cr) and profit (0.55 cr) over the years.	The stock has a low average ROCE of 5.97%, which may not be favorable. The stock has a high average Working Capital Days of 213.62, which may not be favorable. The stock has a high average Cash Conversion Cycle of 132.29, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dr Lalchandani Labs Ltd:
1. Net Profit Margin: 12.83%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: -1.89% (Industry Average ROCE: 11.58%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 6.47% (Industry Average ROE: 12.32%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): -0.49
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.6
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 9.07 (Industry average Stock P/E: 51.19)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.36
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Dr. Lalchandani Labs Ltd. is a Public Limited Listed company incorporated on 02/08/2017 and has its registered office in the State of Delhi, India. Company’s Corporate Identification Number(CIN) is L85320DL2017PLC321605 and registration number is 321605. Currently Company is involved in the business activities of Activities of independent diagnostic/pathological laboratories. Company’s Total Operating Revenue is Rs. 11.28 Cr. and Equity Capital is Rs. 4.33 Cr. for the Year ended 31/03/2022.

INDUSTRY	ADDRESS	CONTACT
Hospitals & Medical Services	M-20, Basement, Greater Kailash, New Delhi Delhi 110048	info@lalchandanipathlab.com http://www.lalchandanipathlab.com

Management
Name	Position Held
Dr. Arjan Lal Chandani	Chairman & Managing Director
Mr. Mohit Lal Chandani	WholeTime Director & CEO
Mrs. Anchal Gupta	Executive Director & CFO
Mr. Rajiv Handa	Independent Director
Mr. Prakash Jhuraney	Independent Director
Mrs. Swati Chandra	Non Executive Director

FAQ

What is the latest intrinsic value of Dr Lalchandani Labs Ltd?

The latest intrinsic value of Dr Lalchandani Labs Ltd as on 15 November 2024 is ₹17.06, which is 5.22% lower than the current market price of ₹18.00.

What is the Market Cap of Dr Lalchandani Labs Ltd?

The Market Cap of Dr Lalchandani Labs Ltd is 7.80 Cr..

What is the current Stock Price of Dr Lalchandani Labs Ltd as on 15 November 2024?

The current stock price of Dr Lalchandani Labs Ltd as on 15 November 2024 is ₹18.0.

What is the High / Low of Dr Lalchandani Labs Ltd stocks in FY 2024?

In FY 2024, the High / Low of Dr Lalchandani Labs Ltd stocks is 28.9/0.00.

What is the Stock P/E of Dr Lalchandani Labs Ltd?

The Stock P/E of Dr Lalchandani Labs Ltd is 9.07.

What is the Book Value of Dr Lalchandani Labs Ltd?

The Book Value of Dr Lalchandani Labs Ltd is 22.4.

What is the Dividend Yield of Dr Lalchandani Labs Ltd?

The Dividend Yield of Dr Lalchandani Labs Ltd is 0.00 %.

What is the ROCE of Dr Lalchandani Labs Ltd?

The ROCE of Dr Lalchandani Labs Ltd is 2.68 %.

What is the ROE of Dr Lalchandani Labs Ltd?

The ROE of Dr Lalchandani Labs Ltd is 8.23 %.

What is the Face Value of Dr Lalchandani Labs Ltd?

The Face Value of Dr Lalchandani Labs Ltd is 10.0.